Commercial positioning case studies

Over 19 days, ICON conducted a focused site engagement programme to increase patient screening and accelerate enrolment of a late phase multinational, multicentre study to evaluate a treatment for pulmonary disease.

The ICON global medical communications group worked with a large pharmaceutical company to identify ways to engage the congress audience and expand the impact of their scientific presentations at a large international meeting.

ICON Outcome Measures found well-validated tools for processing data associated with speech cadence, vocal pitch, and similar measures to evaluate rates of change in neurologic and psychiatric disorders.

A digital health lead at a large pharmaceutical company came to ICON Outcome Measures to find a wearable that could capture continuous cardiac rhythms and be used to detect QT prolongation.

ICON provided a fully localised and tested informational solution for patients that was consistent across platform components for online materials developed to train patients on the consent process.

ICON Market Access played a key role in informing a client’s go-to-market strategy, including analytics around market sizing, a competitive landscape assessment and a benefit design analysis for a long-acting, injectable anti-psychotic drug.

As a result of the multifaceted communication approach with sites and a strong partnership between ICON and sponsor, the study met its protocol-specified enrolment goal just 9 days beyond contracted Last Patient In date (LPI).

ICON delivered a multifaceted omnichannel awareness campaign to provide a seamless customer experience between print and digital channels for a drug to treat PPD.

Through close collaboration with a client, the ICON team provided the support necessary to advance a critical COVID-19 manuscript from outline through submission to acceptance in only 20 days.

ICON developed the first PKU-specific Quality of Life questionnaire available and validated in four age groups and seven languages.

This study was conducted to describe clinical characteristics and current treatment practices for patients with osteoporosis at high risk factor in Japan.

The manufacturer consulted ICON, which had been providing full-service clinical coverage for the PMA study, to economically and seamlessly transition the PMA study participants to the mandated PAS.